Free protein was added was to bring powerful and immediate disease control into the commercial formulation, while also improving manufacturability, dose administration and patient safety 0 4 8 12 -150 -100 -50 0 Aflibercept 2mg and 8mg Tarcocimab (clinical formulation) Disease Control Through the Loading Dose Phase in Wet AMD* CST Change from Baseline (μm) Weeks Powerful and immediate disease control with the 20% unconjugated protein • The 20% unconjugated protein (1 mg) is designed to improve the immediacy of the drying effect during the loading dose phase, “closing the gap" Maintain 6-month predominant durability with the 80% conjugated protein • As seen in tarcocimab pivotal studies to date *Approximate CST changes are plotted based on pivotal clinical studies of approved intravitreal biologics. CST changes for tarcocimab enhanced formulation is a projection 26